Get the Stockscreener App
0.809
4.12%
-0.0314
Moleculin Biotech Inc stock is traded at $0.809, with a volume of 203.32K.
It is down -4.12% in the last 24 hours and down -54.98% over the past month.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
See More
Previous Close:
$0.8404
Open:
$0.83
24h Volume:
203.32K
Relative Volume:
2.48
Market Cap:
$2.84M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-0.0529
EPS:
-15.2954
Net Cash Flow:
$-24.23M
1W Performance:
-46.64%
1M Performance:
-54.98%
6M Performance:
-63.37%
1Y Performance:
-89.67%
1-Day Range:
$0.8058
$0.87
1-Week Range:
$0.8058
$1.52
52-Week Range:
$0.8058
$10.35
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.8074 | 2.84M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.27 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.18 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.56 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.50 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Closing Bell Recap: Moleculin Biotech Inc (MBRX) Ends at 0.84, Reflecting a -15.27 Downturn - The Dwinnex
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
Pediatric Brain Tumors Pipeline 2024: Latest FDA Approvals, - openPR
Moleculin Biotech (NASDAQ:MBRX) CEO Participates in Virtual Investor Segment: 8-K Filing Reveals - Defense World
Moleculin Biotech (NASDAQ:MBRX) CEO Participates in Virtual Investor “What this Means” segment – 8-K Filing News - Defense World
Comparing Biora Therapeutics (NASDAQ:BIOR) and Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Biotech Shares Updates on MIRACLE Trial - TipRanks
Amendment: Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Moleculin Biotech Launches MIRACLE Study for AML - TipRanks
Moleculin Participates in Virtual Investor "What This Means" Segment - Morningstar
StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
What is Roth Capital’s Estimate for MBRX FY2029 Earnings? - Defense World
Moleculin Biotech Issues Positive Business Outlook and Expected Milestones in Recent Press Release On January 8, 2025, Moleculin Biotech, Inc. (NASDAQ: MBRX) released a press release highlighting its business outlook and anticipated upcoming milesto - Defense World
Moleculin Biotech (NASDAQ:MBRX) Corporate Presentation Available OnlineOn January 8, 2025, Moleculin Biotech, Inc. (the “Company”) made public its corporate presentation, which is now accessible on the Company’s official website. The presentation det - Defense World
Moleculin Biotech Advances Annamycin to Phase 3 Trial - TipRanks
Moleculin Highlights Development Progress of Annamycin, Phase 2 - GuruFocus.com
Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026 - PR Newswire
Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.com - Defense World
Bitget Wallet Expands DeSci Ecosystem Access - GlobeNewswire Inc.
Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com - Defense World
Moleculin Biotech, Inc. Posts Investor Presentation on Corporate Website - Defense World
Moleculin Biotech Releases Corporate Presentation Update - TipRanks
Moleculin Biotech stock hits 52-week low at $2.11 By Investing.com - Investing.com Australia
Moleculin Biotech stock hits 52-week low at $2.11 - Investing.com
Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available - The Eastern Progress Online
Moleculin Biotech Discloses Abstract Presentation at ASH Annual MeetingHouston, TX – Moleculin Biotech, Inc. (NASDAQ: MBRX) publicly shared its recent scientific achievement through a press release distributed on December 11, 2024. The communicatio - Defense World
Phathom Pharmaceuticals Submits Citizen Petition to FDA for Correction of Orange Book Listings for VOQUEZNA Tablets - Defense World
Moleculin Participates in Virtual Investor "What this Means" Segment - The Eastern Progress Online
MBRXMoleculin Biotech, Inc. Latest Stock News & Market Updates - StockTitan
What's Going On With Moleculin Biotech Shares Wednesday?Moleculin Biotech (NASDAQ:MBRX) - Benzinga
Moleculin Biotech Advances Annamycin for AML Treatment - TipRanks
Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model - PR Newswire
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - The Eastern Progress Online
Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - The Eastern Progress Online
Moleculin Receives Institutional Review Board Approval for MIRAC - GuruFocus.com
Moleculin to Present at Two Upcoming Investor Conferences - GuruFocus.com
Moleculin Reports Third Quarter 2024 Financial Results and Provi - GuruFocus.com
Moleculin Appoints Leading Expert in Pancreatic Cancer to its Sc - GuruFocus.com
Financial Comparison: Moleculin Biotech (NASDAQ:MBRX) & RedHill Biopharma (NASDAQ:RDHL) - Defense World
Moleculin Biotech Corporate Presentation Posted on Company WebsiteOn November 18, 2024, Moleculin Biotech, Inc. made public a corporate presentation on its official website. This presentation, identified as Exhibit 99.1 in the Current Report on Form - Defense World
What is Roth Capital’s Forecast for MBRX Q1 Earnings? - Defense World
Moleculin Biotech Unveils New Corporate Presentation - TipRanks
New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML - PR Newswire
Moleculin Biotech Amends Clinical Trial Protocol for Phase 3 Trial - Defense World
Armistice Capital, LLC Expands Portfolio with Moleculin Biotech Inc Acquisition - GuruFocus.com
Moleculin (MBRX) Stock Jumps On Accelerated Clinical Trial News - Stocks Telegraph
Moleculin Biotech, Inc. Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia Pivotal Trial to H2 2025 - Marketscreener.com
Moleculin Biotech advances Annamycin AML trial protocol - Investing.com
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):